Agenus Inc.

K Mark Bushell

Olga Ignatovich

Dhan Sidhartha Chand

Emmanuel Cyrille Pascal Briend

Nicola Anne Ramsay

Benjamin Maxime Morin

Zahra Jawad

Beth Wensley

Veronica Franciszka Ilkow

Spencer Campbell

Randi Barbara Gombos

The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.

Anti-TIGIT and anti-CD96 antibodies

The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Antibodies that specifically bind human CD96

Growing community of inventors

Saffron Walden, United Kingdom

K Mark Bushell